Search Result

Results for "

cap

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Androgen Receptor (1) Antibiotic (6) Antifolate (1) Apoptosis (2) Autophagy (2) Bacterial (11) Beta-lactamase (4) Biochemical Assay Reagents (8) CMV (2) DNA Methyltransferase (2) DNA/RNA Synthesis (41) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (14) Eukaryotic Initiation Factor (eIF) (3) Fluorescent Dye (3) HDAC (1) HIV (1) HSV (1) Influenza Virus (38) Isotope-Labeled Compounds (7) Liposome (4) MAPKAPK2 (MK2) (1) Mitochondrial Metabolism (1) MMP (1) NF-κB (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (13) Parasite (1) Polo-like Kinase (PLK) (1) PROTACs (1) SARS-CoV (3) Small Interfering RNA (siRNA) (4) Somatostatin Receptor (2) Thymidylate Synthase (1) TRP Channel (1) Tyrosinase (1) Virus Protease (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Infection (58) Inflammation/Immunology (15) Metabolic Disease (8) Neurological Disease (2)
Click Chemistry:	Azide (1)
Oligonucleotides:	Phospholipids (3) mRNA (4) Human Pre-designed siRNA Sets (4) Cap Analogs (33) siRNAs (4)

152

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159855

CAP 2 hydrochloride Cholesterol-amino-phosphate 2 hydrochloride	Liposome	Others
CAP 2 (Cholesterol-amino-phosphate 2) hydrochloride is Cholesterol-amino-phosphate (CAP) lipid. CAP 2 can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-160957

Cap A (Acetonitrile/Acetic Anhydride, 80/20 v/v)	DNA/RNA Synthesis	Others
Cap A (Acetonitrile/Acetic Anhydride, 80/20 v/v) is a capping reagent that can be used in DNA/RNA synthesis .

HY-160958

Cap B (Acetonitrile/N-methylimidazole /pyridine, 50/20/30 v/v/v)	Biochemical Assay Reagents	Others
Cap B (Acetonitrile/N-methylimidazole /pyridine, 50/20/30 v/v/v) is a biochemical reagent, which contains 50% Acetonitrile, 20 N-methylimidazole and 30% pyridine. Cap B (Acetonitrile/N-methylimidazole /pyridine, 50/20/30 v/v/v) is utilized as capping agent in oligonucleotide synthesis .

HY-P3911

CAP 37 (20-44)	Bacterial	Infection
CAP 37 (20-44) is a peptide based on amino acid residues 20 through 44 of CAP37. CAP37, a Cationic antimicrobial protein of 37 kDa, is a multifunctional protein .

HY-115693

CAP 3	Bacterial	Infection
CAP 3 is a cholic acid-peptide conjugate (CAP) antimicrobial agent. CAP 3 effectively inhibits Gram-negative bacteria, with MIC₉₉ (minimum inhibitory concentration for 99% bacterial killing) values of 8 μM, 16 μM, and 16 μM against E. coli, Klebsiella pneumoniae and Acinetobacter baumannii, respectively. CAP 3 exerts its antibacterial effects by disrupting the structural integrity of the bacterial lipopolysaccharide (LPS) outer membrane. CAP 3 rapidly kills bacteria, inhibits biofilm formation, and effectively combats drug-resistant strains and persistent bacterial infections .

HY-123702

CAP-53194	Polo-like Kinase (PLK)	Cancer
CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing .

HY-143770

Cap-dependent endonuclease-IN-16	Influenza Virus	Infection
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .

HY-143776

Cap-dependent endonuclease-IN-22	Influenza Virus	Infection
Cap-dependent endonuclease-IN-22 is a potent cap-dependent endonuclease (CEN) inhibitor .

HY-P2458

CAP18 (rabbit)	Bacterial	Infection
CAP18 (rabbit) is a 37 amino acids antimicrobial peptide originally isolated from rabbit granulocytes. CAP18 (rabbit) has broad antimicrobial activity against both Gram-positive (IC₅₀, 130-200 nM) and Gram-negative (IC₅₀, 20-100 nM) bacteria. CAP18 (rabbit) has the potential for bacterial sepsis research .

HY-143781

Cap-dependent endonuclease-IN-26	Influenza Virus	Infection
Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC₅₀ of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .

HY-144065

Cap-dependent endonuclease-IN-19	Influenza Virus	Infection
Cap-dependent endonuclease-IN-19 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-19 is a spirocyclic pyridone derivative. Cap-dependent endonuclease-IN-19 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN111410661A, compound 1) .

HY-143749

Cap-dependent endonuclease-IN-6	Influenza Virus	Infection
Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC₅₀=38.21 nM) .

HY-143768

Cap-dependent endonuclease-IN-14	Influenza Virus	Infection
Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .

HY-143769

Cap-dependent endonuclease-IN-15	Influenza Virus	Infection
Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .

HY-144068

Cap-dependent endonuclease-IN-25	Influenza Virus	Infection
Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependent endonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .

HY-143762

Cap-dependent endonuclease-IN-12	Influenza Virus	Infection
Cap-dependent endonuclease-IN-12 (EXP-35) is a potent Cap-dependent endonuclease inhibitor with low cytotoxicity. Cap-dependent endonuclease-IN-12 shows inhibitory activity against H1N1 .

HY-143750

Cap-dependent endonuclease-IN-7	Influenza Virus	Infection
Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)

HY-163621

Cap-dependent endonuclease-IN-28	Influenza Virus	Infection
Cap-dependent endonuclease-IN-28 (Compound 11) is a potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-28 inhibits CEN of TOSV, ANDV, and LACV viruses with IC₅₀ values of 2.4, 0.5, and 4 μM, respectively .

HY-162242

Cap-dependent endonuclease-IN-27	Influenza Virus	Infection
Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC₅₀ = 12.26 nM) .

HY-143766

Cap-dependent endonuclease-IN-13	Influenza Virus	Infection
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .

HY-143752

Cap-dependent endonuclease-IN-8	Influenza Virus	Infection
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .

HY-143755

Cap-dependent endonuclease-IN-9	Influenza Virus	Infection
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .

HY-143743

Cap-dependent endonuclease-IN-2	Influenza Virus	Infection
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .

HY-143744

Cap-dependent endonuclease-IN-3	Influenza Virus	Infection
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .

HY-143775

Cap-dependent endonuclease-IN-20	Influenza Virus	Infection
Cap-dependent endonuclease-IN-20 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 4.82 μM (CN112940009A; DSC801) .

HY-143771

Cap-dependent endonuclease-IN-17	Influenza Virus	Infection
Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC₅₀ of 1.29 μM (CN112898346A; DSC701) .

HY-143747

Cap-dependent endonuclease-IN-5	Influenza Virus	Infection
Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .

HY-143757

Cap-dependent endonuclease-IN-10	Influenza Virus	Infection
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .

HY-144066

Cap-dependent endonuclease-IN-21	Influenza Virus	Infection
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .

HY-144067

Cap-dependent endonuclease-IN-23	Influenza Virus	Infection
Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .

HY-RS01881

CAP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for CAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAP2 Human Pre-designed siRNA Set A CAP2 Human Pre-designed siRNA Set A

HY-RS01880

CAP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAP1 Human Pre-designed siRNA Set A CAP1 Human Pre-designed siRNA Set A

HY-105172

TT-232 cap-232; TLN-232	Somatostatin Receptor	Inflammation/Immunology Cancer
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .

HY-105172A

TT-232 TFA cap-232 TFA; TLN-232 TFA	Somatostatin Receptor Apoptosis	Cancer
TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism .

HY-D0869

CAPS N-Cyclohexyl-3-aminopropanesulfonic acid	Biochemical Assay Reagents	Others Cancer
CAPS, cyclohexylaminopropane sulfonic acid, is a surfactant. CAPS can be used as biological buffer (0.05 M, pH 11) for dialysis .

HY-RS01899

CAPS Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAPS Human Pre-designed siRNA Set A contains three designed siRNAs for CAPS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAPS Human Pre-designed siRNA Set A CAPS Human Pre-designed siRNA Set A

HY-RS01900

CAPS2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAPS2 Human Pre-designed siRNA Set A contains three designed siRNAs for CAPS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAPS2 Human Pre-designed siRNA Set A CAPS2 Human Pre-designed siRNA Set A

HY-123690

Etoposide toniribate cap-7.1	Drug Derivative	Others
Etoposide toniribate is an active compound.

HY-E70081

*mRNA Cap* 2'-O-methyltransferase**	Biochemical Assay Reagents	Others
mRNA Cap 2'-O-methyltransferase uses S-adenosylmethionine (SAM) as a methyl donor to add a methyl group at the 2'-O position of the first nucleotide at the 5’ end of Cap-0 mRNA, resulting in Cap-1 structure. Cap-1 structure promotes translation efficiency, increasing subsequent protein expression .

HY-145974

m7GpppAmpG m7G(5')ppp(5')(2'OMeA)pG	DNA/RNA Synthesis	Others
m7GpppAmpG is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90% .

HY-145977A

m7GpppGmpG ammonium	DNA/RNA Synthesis	Others
m7GpppGmpG ammonium is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 86% .

HY-145974A

m7GpppAmpG ammonium m7G(5')ppp(5')(2'OMeA)pG ammonium	DNA/RNA Synthesis	Others
m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90% .

HY-W340832

*18:1 Biotinyl Cap* PE**	Liposome	Cancer
18:1 Biotinyl Cap PE is a fluorescent lipid, which features a head group that has been altered to include biotinyl cap PE.

HY-150144

Uracil-m7GpppAmpG ammonium	DNA/RNA Synthesis	Others
Uracil-m7GpppAmpG ammonium is a cap analog that can be used for mRNA synthesis.

HY-141472

7-Methylguanosine 5'-diphosphate sodium 7-Methyl-GDP sodium; m7GDP sodium	Endogenous Metabolite	Others
7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, can be used in the synthesis of mRNA cap analogues .

HY-113897

Chloramphenicol 3-acetate	Bacterial	Infection
Chloramphenicol 3-acetate is the main intermediate in the biodegradation of CAP, formed by the acetylation of the 3-hydroxy group of CAP through chloramphenicol acetyltransferase, this is a common resistance mechanism that microbes have against chloramphenicol .

HY-145977

m7GpppGmpG	DNA/RNA Synthesis	Others
m7GpppGmpG is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 86% .

HY-145979

m7GpppUmpG	Nucleoside Antimetabolite/Analog	Others
m7GpppUmpG, an oligonucleotide, is an M ⁷GpppNpG trinucleotide cap analogue. m7GpppUmpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures .

HY-145981

m7GpppCpG	Nucleoside Antimetabolite/Analog	Others
m7GpppCpG, an oligonucleotide, is an M ⁷GpppNpG trinucleotide cap analogue. m7GpppCpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures .

HY-145980

m7GpppUpG	Nucleoside Antimetabolite/Analog	Others
m7GpppUpG, an oligonucleotide, is an M ⁷GpppNpG trinucleotide cap analogue. m7GpppUpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141472

7-Methylguanosine 5'-diphosphate sodium 7-Methyl-GDP sodium; m7GDP sodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, can be used in the synthesis of mRNA cap analogues .

HY-122524

7-Methylguanosine 1 Publications Verification	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Nucleoside Antimetabolite/Analog Endogenous Metabolite DNA/RNA Synthesis
7-Methylguanosine is a modified nucleoside widely present in various RNAs and a key metabolite of the 5'-cap structure of eukaryotic mRNA. 7-Methylguanosine plays important roles in stabilizing RNA structures, regulating translation, and other aspects .

HY-N6772

Cytochalasin E	Alkaloids Structural Classification Microorganisms Pyrrole Alkaloids Classification of Application Fields Source classification Disease Research Fields Cancer	Autophagy
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation .

HY-N0086

N6-Methyladenosine 5+ Cited Publications 6-Methyladenosine; N-Methyladenosine	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Influenza Virus Endogenous Metabolite
N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.

HY-N2362

DL-Alanine DL-2-Aminopropionic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields	Endogenous Metabolite
DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .

HY-139101

Guanosine 5'-triphosphate-5'-adenosine GpppA	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	DNA/RNA Synthesis Endogenous Metabolite
Guanosine 5'-triphosphate-5'-adenosine (GpppA), a 5′ cap analog, can be used for RNA synthesis in vitro. Guanosine 5'-triphosphate-5'-adenosine is a fluorescent substrate analog .

HY-N7647

Methyl brevifolincarboxylate Brevifolincarboxylic acid methyl ester	Infection Structural Classification Natural Products Classification of Application Fields Canarium album (Lour.) Rauesch. Source classification Plants Burseraceae Disease Research Fields	Influenza Virus
Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor. Methyl brevifolincarboxylate has anti-oxidant activity. Methyl brevifolincarboxylate also inhibits platelet aggregation, lipid metabolism and inflammation .

HY-N0086R

N6-Methyladenosine (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Influenza Virus Endogenous Metabolite
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

Cat. No.	Product Name	Chemical Structure

HY-N0086S

N6-Methyladenosine-d3
N6-Methyladenosine-d₃ (6-Methyladenosine-d₃; N-Methyladenosine-d₃) is a deuterium labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.

HY-W751835

Baloxavir-d4

Baloxavir-d₄ (Baloxavir acid-d₄; S-033447-d₄) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d₄ (Baloxavir-d₄ acid), derived from the proagent Baloxavir-d₄ marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d₄ inhibits viral RNA transcription and replication and has potently antiviral activity .

HY-N2362S2

DL-Alanine-d3

DL-Alanine-d₃ is the deuterium labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[1][2][3][4][5][6].

HY-N2362S

DL-Alanine-13C-1

DL-Alanine- ¹³C-1 is the ¹³C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[1][2][3][4][5][6].

HY-N2362S1

DL-Alanine-13C-3

DL-Alanine- ¹³C-3 is the ¹³C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[1][2][3][4][5][6].

HY-D0869S

3-(Cyclohexylamino)-1-propanesulfonic Acid-d17
3-(Cyclohexylamino)-1-propanesulfonic Acid-d₁₇ is the deuterium labeled CAPS[1]. CAPS, cyclohexylaminopropane sulfonic acid, is a surfactant. CAPS can be used as biological buffer (0.05 M, pH 11) for dialysis[2][3].

HY-109025AS

Baloxavir-d5
Baloxavir-d₅ is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].

HY-N0086S2

N6-Methyladenosine-13C4
N6-Methyladenosine- ¹³C₄ (6-Methyladenosine- ¹³C₄; N-Methyladenosine- ¹³C₄) is ¹³C-labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.

HY-N0086S3

N6-Methyladenosine-13C3
N6-Methyladenosine- ¹³C₃ (6-Methyladenosine- ¹³C₃) is ¹³C-labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities .

HY-N2362S5

DL-Alanine-15N

DL-Alanine- ¹⁵N is the ¹⁵N labeled DL-Alanine[1]. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[2][3][4][5][6][7].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks